SELLAS Life Sciences Group, Inc.·4

Sep 26, 7:43 PM ET

Lopez Fabio 4

4 · SELLAS Life Sciences Group, Inc. · Filed Sep 26, 2018

Insider Transaction Report

Form 4
Period: 2018-09-24
Lopez Fabio
Director10% Owner
Transactions
  • Other

    Common Stock

    2018-09-241,521,8630 total
  • Other

    Common Stock

    2018-09-24676,3240 total
  • Other

    Common Stock

    2018-09-24325,7990 total
Footnotes (6)
  • [F1]EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund ("Sely S") distributed 1,521,863 shares to its partners on a pro rata basis, for no consideration.
  • [F2]As a partner of Sely S, Fabio Lopez, received 19,524 of the shares distributed by Sely S.
  • [F3]EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund ("Sely I") distributed 676,324 shares to its partners on a pro rata basis, for no consideration.
  • [F4]As partners of Sely I, Daniel Tafur and Equilibria Capital Management received 13,871 and 107,619, respectively, of the shares distributed by Sely I.
  • [F5]EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund ("Sely II") distributed 325,799 shares to its partners on a pro rata basis, for no consideration.
  • [F6]As partners of Sely II, Fabio Lopez and Daniel Tafur received 6,325 and 2,372, respectively, of the shares distributed by Sely II.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION